Document is current
Any future updates will be listed below
-
Authors
Peters, Anju
Zhao, Xiaohui
Near, Aimee M.
Han, Joseph
Spahn, Joseph D.
Wu, Sze-jung S.
Lindsley, Andrew W.
Le, Tham T.
Wang, Elizabeth J.
Tuly, Rifat
Lee, Inyoung
Ambrose, Christopher S. https://orcid.org/0000-0003-4175-7336
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 17 January 2025
First Online: 19 February 2025
Declarations
:
: Anju T. Peters has received fees for sponsored research from AstraZeneca, Merck and Sanofi, and consultancy fees from AstraZeneca, Chiesi, GSK, Merck, Eli Lilly, and Sanofi. Joseph K. Han has received consultancy fees from AstraZeneca, Genentech, Gossamer Bio, GSK, Novartis, Regeneron Pharmaceuticals and Sanofi. Joseph D. Spahn, Sze-jung S. Wu, Tham T Le, and Christopher S. Ambrose are employees of AstraZeneca and may own stock or stock options in AstraZeneca. Andrew W. Lindsley is an employee of Amgen and owns stock in Amgen. Rifat Tuly, Elizabeth J. Wang, Xiaohui Zhao and Aimee M. Near are employees of IQVIA, which received funding from AstraZeneca to conduct the research study. Inyoung Lee was an employee of IQVIA during the study conduct and is currently employed by AbbVie.
: As a retrospective study using secondary data, no interventions were made to patients during this study. In compliance with the Health Insurance Portability and Accountability Act (HIPAA), patient data included in the analyses were de-identified; therefore, this study was exempt from Institutional Review Board (IRB) review. Permission was obtained to access and use the data from the IQVIA longitudinal prescription (LRx) and medical claims (Dx) databases, which are owned by IQVIA.
